Immunotherapy with hypofractionated radiotherapy in metastatic non-small cell lung cancer: An analysis of the National Cancer Database.

Immunotherapy with hypofractionated radiotherapy in metastatic non-small cell lung cancer: An analysis of the National Cancer Database. Radiother Oncol. 2019 Jun 25;138:75-79 Authors: Bates JE, Morris CG, Milano MT, Yeung AR, Hoppe BS Abstract PURPOSE: Metastatic non-small cell lung cancer (NSCLC) is associated with an exceedingly poor prognosis. Recent advances in immunotherapy offer promise in enhancing overall survival (OS) in these patients. Preclinical evidence suggests that radiotherapy (RT), especially when offered in a high-dose per fraction hypofractionated RT (HRT) as in stereotactic ablative body radiotherapy (SABR), may augment the efficacy of immunotherapy. We aimed to assess the role of RT in patients with metastatic NSCLC receiving immunotherapy in a national hospital-based database. METHODS: Using the National Cancer Database (NCDB), we identified 6,383 patients treated with immunotherapy for metastatic NSCLC and 170,479 patients treated with RT but without immunotherapy. Patients receiving fractional doses of at least 5 Gy were designated as having received HRT, doses
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - Category: Radiology Authors: Tags: Radiother Oncol Source Type: research

Related Links:

Publication date: 15 September 2019Source: Life Sciences, Volume 233Author(s): Humera Memon, Bhoomika M. PatelAbstractLung cancer is the leading cause of cancer-related mortality worldwide. Treatment with immunotherapy has made a significant impact on the outcomes for those patients suffering from lung cancer and its usage is currently an established treatment modality. Immune checkpoint inhibition that has blocking antibodies which target cytotoxic T-lymphocyte antigen-4 (CTLA-4) along with the programmed cell death protein 1 (PD-1) pathway [programmed death - 1/programmed death-ligand 1 (PD-L1)] have shown promising resu...
Source: Life Sciences - Category: Biology Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
Patients with mesothelioma are now eligible for a multicancer clinical trial studying the effectiveness of personalized immunotherapy at the University of California, San Diego Medical Center. The phase I clinical trial involves a combination of Keytruda (pembrolizumab), a proven immunotherapy drug, and an individualized vaccine based upon the genetic mutations found in each patient’s cancer. “This is the future of cancer treatment,” Dr. Ezra Cohen, principal investigator and director of the San Diego Center for Precision Immunotherapy, told The Mesothelioma Center at “Now, we still ha...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
A new meta-analysis compared survival in patients with advanced  non–small cell lung cancer who received immunotherapy vs those who received chemotherapy.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
Squamous cell carcinoma, characterized by large keratinizing and atypical polygonal cells in the respiratory bronchial epithelium [1], affects 30% of patients with lung cancer [2]. Historically, patients with squamous NSCLC were treated with first-line platinum-based chemotherapy [3]. Unlike non-squamous NSCLC, there have been no validated, targetable oncogenic drivers to date. The development and recent approval of targeted immunotherapies, either alone or in combination with platinum-doublet chemotherapy based on improved overall survival, offer a new treatment approach for patients with advanced squamous NSCLC.[4,5] How...
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Conclusion.NLR and PLR may predict the appearance of irAEs in non‐oncogene‐addicted aNSCLC, although this conclusion warrants prospective validation.Implications for Practice.This study was designed to investigate the role of blood biomarkers in predicting the occurrence of immune‐related adverse events (irAEs) in patients with advanced non‐small cell lung cancer receiving immunotherapy. The results of the study suggest a potential predictive role of neutrophil‐to‐lymphocyte ratio and platelet‐to‐lymphocyte ratio as markers for irAE development in this category of patients. These data provide rationale for ...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Lung Cancer Source Type: research
CONCLUSIONS: Pemetrexed augments systemic intra-tumor immune responses through tumor intrinsic mechanisms including immunogenic cell death, T cell-intrinsic mechanisms enhancing mitochondrial biogenesis leading to increased T cell infiltration/activation along with modulation of innate immune pathways, significantly enhanced in combination with PD-1 pathway blockade. PMID: 31409612 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Abstract In recent years, immunotherapy has become an innovative technology for cancer therapy with the discovery of immunological checkpoints. It has shown great potential in a variety of advanced cancer treatments. Particularly, significant progress has been achieved in the understanding of programmed death-1/programmed death ligand-1 (PD-1/ PD-L1) pathway. Nivolumab, a human immunoglobulin (Ig)G4 PD-1 monoclonal antibody, was the first PD-1 inhibitor approved in the treatment of advanced non-small-cell lung cancer (NSCLC). Nivolumab has become a mainstay of first-line treatment of advanced/metastatic NSCLC with...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - Category: Drugs & Pharmacology Authors: Tags: Biomed Pharmacother Source Type: research
CONCLUSION: Nivolumab plus ipilimumab represent the most promising immunotherapy combination for the treatment of advanced NSCLC patients; safety, tolerability and efficacy of new immune modulators (in monotherapy and in immune combinations) must be further assessed in future studies. PMID: 31400270 [PubMed - as supplied by publisher]
Source: Current Clinical Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Curr Clin Pharmacol Source Type: research
o Tommasi De Summa Non-small-cell lung cancer, histologically classified into adenocarcinoma (AD) and squamous cell carcinoma, is one of the most deadly malignancies worldwide. Lung AD (LUAD) could benefit of a plethora of target therapies and, in the last few years, also of immunotherapies. Here we focused on a real-life cohort of LUAD and The Cancer Genome Atlas (TCGA)-LUAD dataset aiming to gain insights into the immune contexture of such a malignancy. We explored the mutational status of 41 genes and the expression of 94 genes, related to immune-checkpoint, inflammation, and stromal microenvironment. Surprisi...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
More News: Cancer | Cancer & Oncology | Databases & Libraries | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Radiology | Statistics